All In Biotech

Drug Trial Radar · NCT04278768

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

366

Planned (sponsor's estimate)

Start

Jul 6, 2020

Primary completion

Apr 1, 2026

Study completion Apr 1, 2026

Sponsor

Lead sponsor
Curis, Inc.Industry
Sponsor type
Industry
First posted
Feb 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS). Patients enrolling in the Phase 1 dose escalation of the study must meet one of the following criteria prior to consenting to the study: * Relapse/refractory (R/R) AML with FMS-like tyrosine kinase-3 (FLT3) mutations who have been previously treated with a FLT3 inhibitor * R/R AML with spliceosome mutations of splicing factor 3B subunit 1 (SF3B1) or U2AF1 * R/R hrMDS with spliceosome mutations of SF3B1 or U2 small nuclear RNA auxiliary factor 1 (U2AF1) * Number of pretreatments: 1 or 2 The Phase 2a Dose Expansion will be in 3 Cohorts of patients: 1. R/R AML with FLT3 mutations who have been previously treated with a FLT3 inhibitor; 2. R/R AML with spliceosome mutations of SF3B1 or U2AF1; and 3. R/R hrMDS (Revised International Prognostic Scoring System \[IPSS-R\] score \> 3.5) with spliceosome mutations of SF3B1 or U2AF1. All patients above have had ≤ 2 lines of prior systemic anticancer treatment. In previous versions of this protocol there was a Phase 1b portion of the study, in which patients with AML or hrMDS received CA-4948 in combination with venetoclax. This part of the study is no longer open for enrollment.

Conditions

  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome

Interventions

  • EmavusertibDrug

    Emavusertib is formulated as a tablet for oral administration for BID dosing in consecutive 28-day cycles. Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 kinase plays an essential role in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways and these pathways are frequently dysregulated in non-Hodgkin's lymphoma and AML/MDS malignancies.

  • VenetoclaxDrug

    Ventoclax is B-cell lymphoma-2 (BCL-2) inhibitor. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level. This arm of the study has been closed to enrollment.

  • EmavusertibDrug

    Emavusertib is formulated as a tablet for oral administration for BID dosing for 21 days (Days 1-21) of a 28-day Cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine Maximum Tolerated Dose (MTD) of emavusertib (CA-4948) monotherapy (Phase 1)Time frame: 28 days
  2. Determine the Recommended Phase 2 Dose (RP2D) of emavusertib monotherapy (Phase 1)Time frame: 24 months
  3. Determine Maximum Tolerated Dose (MTD) of emavusertib in combination with venetoclax (Phase 1b)Time frame: 28 days
  4. Determine the Recommended Phase 2 Dose (RP2D) of emavusertib in combination with venetoclax (Phase 1b)Time frame: 24 months
  5. To assess anti-cancer activity (Phase 2a - AML patients)Time frame: 24 months
  6. To assess anti-cancer activity (Phase 2a - hrMDS patients)Time frame: 24 months
  7. To assess safety (Phase 1b)Time frame: 24 months

Locations

32 sites in 8 countries. Site status is shown where the registry gives one.

  • Moffitt Cancer Center

    Tampa, Florida

  • Winship Cancer Institute

    Atlanta, Georgia

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • University of Chicago Medical Center

    Chicago, Illinois

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists

    Omaha, Nebraska

  • University of Rochester Medical Center

    Rochester, New York

  • Albert Einstein Medical College

    The Bronx, New York

  • Novant Health Hematology - Forsyth

    Winston-Salem, North Carolina

  • The Ohio State University Wexner Medical Center - James Cancer Hospital

    Columbus, Ohio

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Vseobecna Fakultni nemocnice v Praze

    Prague, Czechia

  • Service d'hématologie clinique CHU de Nice

    Nice, France

  • APHP - Sorbonne Universite

    Paris, France

  • APHP - Hopital Saint Louis

    Paris, France

  • Marien Hospital Dusseldorf; Klinik fur Onkologie und Hamatologie, Palliativmedizin

    Düsseldorf, Germany

  • Universitätsklinikum Hamburg-Eppendorf (UKE)

    Hamburg, Germany

  • Universitatsklinikum Leipzig; Medizinische Klinik und Poliklinik I

    Leipzig, Germany

  • Klinikum rechts der Isar der Technischen Universitat Munchen

    München, Germany

  • Universitatsklinikum Munster

    Münster, Germany

  • Soroka University MC

    Beersheba, Israel

  • Edith Wolfson Medical Center

    Holon, Israel

  • Hadassah University MC

    Jerusalem, Israel

  • Azienda Ospedaliera Santa Croce e Carle

    Cuneo, Italy

  • Instituto Romagnolo per lo Studio dei Tumori "Dino Amadori"

    Meldola, Italy

  • Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz

    Gdansk, Poland

  • University Hospital in Krakow

    Krakow, Poland

  • Hospital de la Santa Creu I Sant Pau (Neuvo Hospital)

    Barcelona, Spain

  • Hospital Universitaro del a Princesa

    Madrid, Spain

  • MD Anderson Cancer Center Madrid

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.